CYTOGEN CORP
S-8, EX-5, 2000-10-23
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: CYTOGEN CORP, S-8, EX-4.2, 2000-10-23
Next: CYTOGEN CORP, S-8, EX-23.1, 2000-10-23




                               Buchanan Ingersoll
                            Professional Corporation
                         (Incorporated in Pennsylvania)
                                    Attorneys
                              650 College Road East
                           Princeton, New Jersey 08540

                                                  October 23, 2000

Cytogen Corporation
600 College Road East CN 5308
Princeton, New Jersey   08540

Gentlemen:

     We have acted as counsel to  Cytogen  Corporation,  a Delaware  corporation
(the "Company"),  in connection with the filing by the Company of a Registration
Statement on Form S-8 (the  "Registration  Statement")  together  with a Reoffer
Prospectus (the "Prospectus")  which relates to the public resale,  from time to
time, of an aggregate of 2,850,000 shares of the Company's  Common Stock,  $0.01
par value per share,  which have been or may be  acquired  upon the  exercise of
stock options granted pursuant to: (i) a written compensatory agreement granting
options  outside of any of the Company's  stock option plans to H. Joseph Reiser
dated  August 24, 1998 (the  "Reiser  Agreement");  (ii) a written  compensatory
agreement granting options outside of any of the Company's stock option plans to
Lawrence  Hoffman dated July 10, 2000 (the "Hoffman  Agreement");  and (iii) the
Company's  1999 Stock Option Plan for  Non-Employee  Directors (the "1999 Plan";
collectively,  the Reiser Agreement, the Hoffman Agreement and the 1999 Plan are
referred  to herein as the  "Plans").  The shares  underlying  the  Registration
Statement  and  Prospectus  are  collectively  referred  to  hereinafter  as the
"Shares."

     In  connection  with the  Registration  Statement and  Prospectus,  we have
examined  such  corporate  records  and  documents,  other  documents,  and such
questions of law as we have deemed necessary or appropriate for purposes of this
opinion. On the basis of such examination, it is our opinion that:

     1. The issuance of the Shares has been duly and validly authorized; and

     2. The Shares  underlying  the Plans,  when issued,  delivered  and sold in
accordance with the terms of the Plans,  will be legally issued,  fully paid and
non-assessable.

     We  hereby  consent  to the  filing  of this  opinion  as  Exhibit 5 to the
Registration Statement and Prospectus.

                                         Very truly yours,

                                         BUCHANAN INGERSOLL
                                         PROFESSIONAL CORPORATION

                                         /s/ Raymond Thek
                                         ---------------------------------------
                                         By:  Raymond Thek, a member of the firm



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission